Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability

Carcinogenesis

Volumn 35, Issue 9, 2014, Pages 1951-1961

  Correa, Rohann J M ^a,b   Valdes, Yudith Ramos ^a   Peart, Teresa M ^a,b   Fazio, Elena N ^a   Bertrand, Monique ^a,b   McGee, Jacob ^a,b   Préfontaine, Michel ^a,b   Sugimoto, Akira ^a,b   DiMattia, Gabriel E ^a,b   Shepherd, Trevor G ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; BECLIN 1; CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; ASCITES TUMOR CELL; AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; AUTOPHAGY BLOCKADE; CARCINOMA CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; UPREGULATION;

ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; ASCITES; AUTOPHAGY; BENZYLAMINES; CELL LINE, TUMOR; CELL SURVIVAL; CHLOROQUINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; QUINOXALINES; SPHEROIDS, CELLULAR;

EID: 84906828707     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu049     Document Type: Article

References (50)

1. Howlader,N. et al. (eds) (2013). SEER Cancer Statistics Review, 1975- 2010. National Cancer Institute, Bethesda, MD.
2. Coleman,R.L. et al. (2013) Latest research and treatment of advancedstage epithelial ovarian cancer. Nat. Rev. Clin. Oncol., 10, 211-224.
3. Ledermann,J. et al. (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med., 366, 1382-1392.
4. Perren,T.J. et al.; ICON7 Investigators. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med., 365, 2484-2496.
5. Burger,R.A. et al.; Gynecologic Oncology Group. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med., 365, 2473-2483.
6. Hanrahan,A.J. et al. (2012) Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov., 2, 56-67.
7. TCGA. (2011) The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-615.
8. Seiden,M.V. et al. (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinumresistant ovarian and primary peritoneal malignancies. Gynecol. Oncol., 104, 727-731.
9. Bookman,M.A. et al. (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol., 21, 283-290.
10. Schilder,R.J. et al. (2009) Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol., 113, 21-27.
11. Behbakht,K. et al. (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol. Oncol., 123, 19-26.
12. Ferraro,E. et al. (2008) Apoptosome-deficient cells lose cytochrome c through proteasomal degradation but survive by autophagy-dependent glycolysis. Mol. Biol. Cell, 19, 3576-3588.
13. Lum,J.J. et al. (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell, 120, 237-248.
14. Boya,P. et al. (2005) Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol., 25, 1025-1040.
15. Degtyarev,M. et al. (2008) Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J. Cell Biol., 183, 101-116.
16. Cao,C. et al. (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res., 66, 10040-10047.
17. Katayama,M. et al. (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ., 14, 548-558.
18. Amaravadi,R.K. et al. (2007) Autophagy inhibition enhances therapyinduced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest., 117, 326-336.
19. Abedin,M.J. et al. (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ., 14, 500-510.
20. Kipps,E. et al. (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat. Rev. Cancer, 13, 273-282.
21. Correa,R.J. et al. (2012) Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis, 33, 49-58.
22. Burleson,K.M. et al. (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol., 93, 170-181.
23. Allen,H.J. et al. (1987) Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Exp. Cell Biol., 55, 194-208.
24. Iwanicki,M.P. et al. (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov., 1, 144-157.
25. Shield,K. et al. (2009) Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol. Oncol., 113, 143-148.
26. Shepherd,T.G. et al. (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat. Protoc., 1, 2643-2649.
27. Taylor-Harding,B. et al. (2010) Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol. Oncol., 119, 549-556.
28. Manning,B.D. et al. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
29. Calleja,V. et al. (2009) Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol., 7, e17.
30. Sarbassov,D.D. et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
31. Choi,A.M. et al. (2013) Autophagy in human health and disease. N. Engl. J. Med., 368, 651-662.
32. Mizushima,N. et al. (2010) Methods in mammalian autophagy research. Cell, 140, 313-326.
33. Hu,C. et al. (2008) The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg. Med. Chem., 16, 7888-7893.
34. Liu,J. et al. (2011) Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell, 147, 223-234.
35. Burleson,K.M. et al. (2004) Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis, 21, 685-697.
36. Chou,T.C. et al. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55.
37. White,E. et al. (2009) The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res., 15, 5308-5316.
38. Lu,Z. et al. (2008) The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest., 118, 3917-3929.
39. Degenhardt,K. et al. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell, 10, 51-64.
40. Hamilton,G. (1998) Multicellular spheroids as an in vitro tumor model. Cancer Lett., 131, 29-34.
41. Tang,M.K. et al. (2010) c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signalregulated kinase.. Neoplasia, 12, 128-138.
42. Yoshida,Y. et al. (2008) Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin. Int. J. Oncol., 32, 673-681.
43. Xing,H. et al. (2007) Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol. Rep., 17, 117-122.
44. Xing,H. et al. (2005) Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J. Cancer Res. Clin. Oncol., 131, 511-519.
45. Green,S.K. et al. (2004) Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol. Cancer Ther., 3, 149-159.
46. Sotelo,J. et al. (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med., 144, 337-343.
47. Briceno,E. et al. (2003) Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg. Focus, 14, e3.
48. McAfee,Q. et al. (2012) Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc. Natl. Acad. Sci. U. S. A., 109, 8253-8258.
49. Salabei,J.K. et al. (2013) PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. Biochem. J., 451, 375-388.
50. Vakifahmetoglu-Norberg,H. et al. (2013) Chaperone-mediated autophagy degrades mutant p53. Genes Dev., 27, 1718-1730.